Cidara Therapeutics, Inc. (NASDAQ:CDTX) Expected to Post FY2025 Earnings of $12.63 Per Share

Cidara Therapeutics, Inc. (NASDAQ:CDTX - Free Report) - Stock analysts at HC Wainwright raised their FY2025 EPS estimates for shares of Cidara Therapeutics in a report issued on Thursday, April 25th. HC Wainwright analyst E. Arce now forecasts that the biotechnology company will earn $12.63 per share for the year, up from their previous estimate of $12.60. HC Wainwright currently has a "Buy" rating and a $120.00 price target on the stock. The consensus estimate for Cidara Therapeutics' current full-year earnings is ($13.00) per share. HC Wainwright also issued estimates for Cidara Therapeutics' FY2026 earnings at $18.85 EPS and FY2027 earnings at $40.32 EPS.

Several other research analysts have also weighed in on CDTX. WBB Securities reiterated a "strong-buy" rating and issued a $40.00 price objective on shares of Cidara Therapeutics in a research note on Thursday. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Cidara Therapeutics in a research note on Tuesday. Finally, Needham & Company LLC increased their price objective on Cidara Therapeutics from $3.00 to $25.00 and gave the stock a "buy" rating in a report on Thursday. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Cidara Therapeutics presently has an average rating of "Buy" and a consensus price target of $71.25.

Cidara Therapeutics Stock Down 2.8 %

Shares of CDTX traded down $0.37 during trading hours on Friday, reaching $12.63. The company's stock had a trading volume of 199,445 shares, compared to its average volume of 50,035. The firm has a market cap of $57.59 million, a price-to-earnings ratio of -2.63 and a beta of 0.98. The company has a 50 day moving average of $15.35 and a two-hundred day moving average of $15.31. Cidara Therapeutics has a 1-year low of $10.00 and a 1-year high of $29.60.

Institutional Investors Weigh In On Cidara Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of CDTX. Raymond James Financial Services Advisors Inc. boosted its position in Cidara Therapeutics by 25.2% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 79,119 shares of the biotechnology company's stock worth $75,000 after purchasing an additional 15,912 shares during the period. Pale Fire Capital SE bought a new stake in shares of Cidara Therapeutics during the 3rd quarter worth $51,000. Finally, Flagship Harbor Advisors LLC acquired a new position in Cidara Therapeutics in the 3rd quarter valued at $28,000. Institutional investors and hedge funds own 35.82% of the company's stock.

About Cidara Therapeutics

Cidara Therapeutics, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates.